AccuStem Sciences is introducing the microRNA Signature Classifier (MSC) blood test for US lung cancer screening programs, aiming to reach 15 million at-risk individuals annually. The test, proven effective in reducing false positives, could enhance early detection and treatment, potentially saving on healthcare costs.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay